167 related articles for article (PubMed ID: 11802587)
21. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately.
Saenger R; Maechler G; Potreck M; Zepp F; Knuf M; Habermehl P; Schuerman L
Vaccine; 2005 Jan; 23(9):1135-43. PubMed ID: 15629356
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms underlying adverse reactions to vaccines.
Siegrist CA
J Comp Pathol; 2007 Jul; 137 Suppl 1():S46-50. PubMed ID: 17559869
[TBL] [Abstract][Full Text] [Related]
23. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
van der Maas NA; David S; Kemmeren JM; Vermeer-de Bondt PE
Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2732-7. PubMed ID: 18225797
[TBL] [Abstract][Full Text] [Related]
24. [Adverse events after vaccination].
Nøkleby H; Bergsaker MA
Tidsskr Nor Laegeforen; 2006 Oct; 126(19):2541-4. PubMed ID: 17028637
[TBL] [Abstract][Full Text] [Related]
25. Improving global monitoring of vaccine safety: a quantitative analysis of adverse event reports in the WHO Adverse Reactions Database.
Letourneau M; Wells G; Walop W; Duclos P
Vaccine; 2008 Feb; 26(9):1185-94. PubMed ID: 18243428
[TBL] [Abstract][Full Text] [Related]
26. Adverse event reports following yellow fever vaccination.
Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
[TBL] [Abstract][Full Text] [Related]
27. Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine.
McMahon AW; Iskander JK; Haber P; Braun MM; Ball R
Vaccine; 2008 Jan; 26(3):427-9. PubMed ID: 18093701
[TBL] [Abstract][Full Text] [Related]
28. Developmental regression and autism reported to the Vaccine Adverse Event Reporting System.
Woo EJ; Ball R; Landa R; Zimmerman AW; Braun MM;
Autism; 2007 Jul; 11(4):301-10. PubMed ID: 17656395
[TBL] [Abstract][Full Text] [Related]
29. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?
Halperin SA; Sweet L; Baxendale D; Neatby A; Rykers P; Smith B; Zelman M; Maus D; Lavigne P; Decker MD
Pediatr Infect Dis J; 2006 Mar; 25(3):195-200. PubMed ID: 16511379
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis B vaccination and adult associated gastrointestinal reactions: a follow-up analysis.
Geier DA; Geier MR
Hepatogastroenterology; 2002; 49(48):1571-5. PubMed ID: 12397738
[TBL] [Abstract][Full Text] [Related]
31. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; West DJ;
Pharmacoepidemiol Drug Saf; 2002; 11(3):189-202. PubMed ID: 12051118
[TBL] [Abstract][Full Text] [Related]
32. Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005.
Dobardzic A; Izurieta H; Woo EJ; Iskander J; Shadomy S; Rupprecht C; Ball R; Braun MM
Vaccine; 2007 May; 25(21):4244-51. PubMed ID: 17382435
[TBL] [Abstract][Full Text] [Related]
33. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents.
Bergen R; Black S; Shinefield H; Lewis E; Ray P; Hansen J; Walker R; Hessel C; Cordova J; Mendelman PM
Pediatr Infect Dis J; 2004 Feb; 23(2):138-44. PubMed ID: 14872180
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacovigilance of vaccines].
Autret-Leca E; Bensouda-Grimaldi L; Jonville-Béra AP; Beau-Salinas F
Arch Pediatr; 2006 Feb; 13(2):175-80. PubMed ID: 16343870
[TBL] [Abstract][Full Text] [Related]
35. Postlicensure epidemiology of childhood vaccination: the Danish experience.
Hviid A
Expert Rev Vaccines; 2006 Oct; 5(5):641-9. PubMed ID: 17181438
[TBL] [Abstract][Full Text] [Related]
36. Rotavirus vaccines: targeting the developing world.
Glass RI; Bresee JS; Turcios R; Fischer TK; Parashar UD; Steele AD
J Infect Dis; 2005 Sep; 192 Suppl 1():S160-6. PubMed ID: 16088799
[TBL] [Abstract][Full Text] [Related]
37. Evaluating vaccine safety before and after licensure.
Clemens J
Bull World Health Organ; 2000; 78(2):218-9. PubMed ID: 10743289
[TBL] [Abstract][Full Text] [Related]
38. The science of evaluation of adverse events associated with vaccination.
Halsey NA
Semin Pediatr Infect Dis; 2002 Jul; 13(3):205-14. PubMed ID: 12199617
[TBL] [Abstract][Full Text] [Related]
39. The complicated task of monitoring vaccine safety.
Ellenberg SS; Chen RT
Public Health Rep; 1997; 112(1):10-20; discussion 21. PubMed ID: 9018282
[TBL] [Abstract][Full Text] [Related]
40. Combination vaccines: postlicensure safety evaluation.
Chen RT; Pool V; Takahashi H; Weniger BG; Patel B
Clin Infect Dis; 2001 Dec; 33 Suppl 4():S327-33. PubMed ID: 11709768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
